TELA BIO INC (TELA) Stock Price & Overview

NASDAQ:TELAUS8723811084

Current stock price

0.7781 USD
+0.03 (+3.75%)
At close:
0.7566 USD
-0.02 (-2.76%)
After Hours:

The current stock price of TELA is 0.7781 USD. Today TELA is up by 3.75%. In the past month the price increased by 8.46%. In the past year, price decreased by -47.07%.

TELA Key Statistics

52-Week Range0.6671 - 2.2
Current TELA stock price positioned within its 52-week range.
1-Month Range0.69 - 0.929
Current TELA stock price positioned within its 1-month range.
Market Cap
34.057M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.89
Dividend Yield
N/A

TELA Stock Performance

Today
+3.75%
1 Week
+5.18%
1 Month
+8.46%
3 Months
-31.14%
Longer-term
6 Months -51.97%
1 Year -47.07%
2 Years -86.28%
3 Years -92.69%
5 Years -94.78%
10 Years N/A

TELA Stock Chart

TELA BIO INC / TELA Daily stock chart

TELA Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to TELA. When comparing the yearly performance of all stocks, TELA is a bad performer in the overall market: 91.65% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

TELA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to TELA. TELA has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TELA Earnings

On November 13, 2025 TELA reported an EPS of -0.19 and a revenue of 20.69M. The company beat EPS expectations (6.39% surprise) and missed revenue expectations (-6.91% surprise).

Next Earnings DateMar 24, 2026
Last Earnings DateNov 13, 2025
PeriodQ3 / 2025
EPS Reported-$0.19
Revenue Reported20.689M
EPS Surprise 6.39%
Revenue Surprise -6.91%

TELA Forecast & Estimates

11 analysts have analysed TELA and the average price target is 3.52 USD. This implies a price increase of 352.26% is expected in the next year compared to the current price of 0.7781.

For the next year, analysts expect an EPS growth of 38.59% and a revenue growth 7.66% for TELA


Analysts
Analysts81.82
Price Target3.52 (352.38%)
EPS Next Y38.59%
Revenue Next Year7.66%

TELA Groups

Sector & Classification

TELA Financial Highlights

Over the last trailing twelve months TELA reported a non-GAAP Earnings per Share(EPS) of -0.89. The EPS increased by 47.34% compared to the year before.


Income Statements
Revenue(TTM)77.06M
Net Income(TTM)-39.00M
Industry RankSector Rank
PM (TTM) N/A
ROA -63.32%
ROE -2504.69%
Debt/Equity 26.65
Chartmill High Growth Momentum
EPS Q2Q%54.76%
Sales Q2Q%9.14%
EPS 1Y (TTM)47.34%
Revenue 1Y (TTM)12.24%

TELA Ownership

Ownership
Inst Owners72.12%
Shares43.77M
Float39.58M
Ins Owners9.24%
Short Float %1.59%
Short Ratio3.62

About TELA

Company Profile

TELA logo image TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company is headquartered in Malvern, Pennsylvania and currently employs 209 full-time employees. The company went IPO on 2019-11-08. The firm is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The firm's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.

Company Info

IPO: 2019-11-08

TELA BIO INC

1 Great Valley Parkway, Suite 24

Malvern PENNSYLVANIA 19355 US

CEO: Antony Koblish

Employees: 209

TELA Company Website

TELA Investor Relations

Phone: 13026587581

TELA BIO INC / TELA FAQ

Can you describe the business of TELA BIO INC?

TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company is headquartered in Malvern, Pennsylvania and currently employs 209 full-time employees. The company went IPO on 2019-11-08. The firm is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The firm's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.


Can you provide the latest stock price for TELA BIO INC?

The current stock price of TELA is 0.7781 USD. The price increased by 3.75% in the last trading session.


What is the dividend status of TELA BIO INC?

TELA does not pay a dividend.


How is the ChartMill rating for TELA BIO INC?

TELA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Can you provide the sector and industry classification for TELA BIO INC?

TELA BIO INC (TELA) operates in the Health Care sector and the Health Care Equipment & Supplies industry.


Is TELA BIO INC (TELA) expected to grow?

The Revenue of TELA BIO INC (TELA) is expected to grow by 7.66% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.